Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 841 across all filing types
Latest filing 2015-08-11 Earnings Release
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Amerikanska FDA godkänner Zubsolv® för initiering av underhållsbehandling med buprenorfin för patienter som lider av opiatberoende
Earnings Release Classification · 1% confidence The document is a press release from Orexo AB dated August 11, 2015, announcing that the US FDA has approved an expanded indication for their drug Zubsolv® (initiation of maintenance treatment for opioid dependence). It details the clinical studies supporting this approval and provides commentary from management regarding the business impact and upcoming conference call. This type of announcement, which details significant operational/regulatory news and financial performance highlights (market share increase), is characteristic of an Earnings Release (ER) or a general press release announcing material news. Since it focuses on the immediate results and business impact rather than being a comprehensive annual or quarterly financial report (10-K or IR), 'ER' (Earnings Release) is the most appropriate classification for a material announcement of this nature, even though it's not strictly tied to a quarterly reporting period, as it contains key business updates and management commentary often associated with earnings events. It is not a transcript (CT), a formal report (10-K/IR), or a proxy statement (DEF 14A/PSI). FY 2015
2015-08-11 Swedish
Major Shareholding Notification 2015
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding for Orexo AB by Handelsbanken Fonder AB. Specifically, it shows the 'Before the transaction' and 'After the transaction' share counts, the reason for the notification ('Sell'), and the resulting percentage of voting rights. The structure and content—tracking ownership changes and reporting thresholds—are characteristic of a Major Shareholding Notification. This aligns directly with the definition for 'Major Shareholding Notification' (Code: MRQ). The document is short and contains specific transactional data rather than a comprehensive report or an announcement about a report.
2015-08-06 English
ZUBSOLV® Market Access Update on Agreement with CVS Caremark and Announcement of New Exclusive Agreement in Managed Medicaid
Regulatory Filings Classification · 1% confidence The document is a press release dated August 4, 2015, announcing changes to the formulary position of ZUBSOLV® with CVS Caremark and a new exclusive agreement in Managed Medicaid. It discusses market share, financial impact estimates, and strategic opportunities. This type of announcement, detailing specific business developments, market access changes, and strategic updates, is characteristic of an Earnings Release (ER) or a general business update. Since it focuses on the immediate financial and market impact of payer negotiations rather than a comprehensive review of the entire fiscal period (like a 10-K or IR), ER is a strong candidate. However, the content is highly focused on market access and payer negotiations, which often falls under general business updates or investor relations material. Given the options, it is a press release detailing recent business performance and outlook related to a specific product's market access, which aligns closely with the function of an Earnings Release (ER) which provides key highlights and immediate results/updates, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Since it is a proactive press release detailing market performance and strategic wins/losses, ER is the most fitting category for key financial/market highlights. It is not a full report (10-K, IR), a transcript (CT), or a specific governance/director filing. The length (9686 chars) suggests it is more than just a brief announcement of a report (RPA).
2015-08-04 English
Zubsolv® uppdatering om avtal med CVS Caremark och information om nytt exklusivt avtal inom Managed Medicaid
Regulatory Filings Classification · 1% confidence The document is a press release from Orexo AB dated August 4, 2015, announcing changes regarding the reimbursement status of their drug Zubsolv® by CVS Caremark and the signing of a new exclusive agreement within Managed Medicaid. This type of announcement, detailing strategic business updates, contract changes, and market access developments, is typically classified as a general business or investor relations communication. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA), and it specifically concerns strategic business developments and contract negotiations, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, or potentially 'Capital/Financing Update' (CAP) if the focus was purely on financing, but here it is market access/contractual. Given the options, RNS serves as the best catch-all for significant, non-standardized corporate news releases that aren't explicitly covered by other codes like ER or CT. It is not a report itself, but an announcement of business events.
2015-08-04 Swedish
Antal aktier och röster i Orexo
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release dated July 31, 2015, titled "Antal aktier och röster i Orexo" (Number of shares and votes in Orexo). The text explicitly states that the number of shares and votes has changed because the company has repurchased previously issued C-shares. It then details the total number of shares (stamaktier and C-aktier) and the total number of votes. This content directly relates to changes in the company's share capital structure due to share repurchase activity. This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS), which covers share repurchase/issuance.
2015-07-31 Swedish
Number of shares and votes in Orexo
Transaction in Own Shares Classification · 1% confidence The document is a short press release announcing a change in the number of shares and votes due to the repurchase of class C shares. This action directly relates to the company's own stock transactions. Reviewing the definitions, 'Transaction in Own Shares (Code: POS)' is defined as 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. The content explicitly states the company 'repurchased the entire issue of class C shares' and details the resulting total share count. This fits the POS category perfectly, rather than a general financing update (CAP) or a major shareholding notification (MRQ) which usually concerns external investors crossing thresholds.
2015-07-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.